Clinical responsive DNA therapy for individual renal cell carcinoma

摘要

The proposed technical solution relates to the field of personalized medicine for oncological diseases, and specifically to test systems used to evaluate the efficacy of therapy for kidney cancer using the preparation sorafenib. Using the given method will make it possible to select a drug for treating a patient based on an analysis of objective individual changes arising in abnormal tissue. The solution utilizes the construction of a classifier that provides a prognosis of the clinical efficacy of the use of sorafenib for individual cancer patients, dividing said patients into responsive and unresponsive groups. A mathematical formula for calculating a gene signature is the basis for all calculations being executed to help divide the patients into the groups of those who are responsive to and those who are not responsive to the drug therapy being conducted with sorafenib. The present invention makes it possible to increase the degree of reliability with which the clinical efficacy of using sorafenib to treat kidney carcinoma in patients is evaluated.